IFNA2 and susceptibility to pneumonia measurement: In another retrospective cohort study, ARB in combination with interferon α2b (IFN‐α2b) was compared with IFN‐α2b monotherapy, and the combination therapy significantly accelerated the absorption of pneumonia (p = .037), suggesting that the combination of ARB and IFN‐α2b may be beneficial in reducing lung inflammation in patients with mild coronavirus disease 2019 (COVID‐19) but is not effective in accelerating viral clearance (p = .057) or reducing the length of hospital stay (p = .056).104